- -Risk-reducing salpingo-oophorectomy with mini-invasive surgical approach in BRCA1-2 mutation carriers is a safe procedure.
- -The routine use of peritoneal biopsies does not improve the detection of occult malignancies.
- -Adherence to guidelines and to their timetable are essential to further reduce the risk of ovarian cancer.
International guidelines recommend risk-reducing salpingo-oophorectomy (RRSO) in BRCA1-2 mutations carriers to decrease ovarian cancer occurrence. In this prospective study, we describe the incidence of occult malignancies and the surgical outcomes in asymptomatic BRCA mutation carriers submitted to RRSO.
Data on BRCA1-2 carriers undergoing RRSO with peritoneal washing and peritoneal/omental biopsies (PeS), between January 2019 until March 2021, were prospectively collected.
A total of 132 patients were enrolled: 74 BRCA1 and 58 BRCA2 mutation carriers. 31.1% women underwent RRSO and PeS (16.2% of BRCA1 and 50% of BRCA2 carriers), while 68.9% patients were submitted also to concomitant hysterectomy. Almost all the procedures (99.2%) were performed by minimally invasive surgery. Postoperative complications occurred in twelve patients (9.1%): 10 in the concomitant hysterectomy group and two complications in the RRSO group. At the final pathological examination, 6 (4.5%) occult carcinomas were diagnosed: 3 fallopian tube carcinomas, one ovarian carcinoma and two serous tubal intraepithelial carcinomas (STICs), with negative PeS. Median age of occult carcinomas patients at RRSO was 54 (range: 48–79) years. The mean follow up was 20 (range: 7–34) months. During the follow up, no primary peritoneal cancer has been diagnosed.
Occult pathologic findings in RRSO occurred in 4.5% (3% invasive carcinomas, STIC 1.5%) among our patients. The routine use of peritoneal biopsies does not improve the detection of occult malignancies. Our data confirm the importance of timely performing RRSO in BRCA1-2 carriers.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to European Journal of Surgical Oncology
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Hereditary ovarian cancers: state of the art.Minerva Med. 2019; 110https://doi.org/10.23736/S0026-4806.19.06091-9
- Evaluation of transvaginal ultrasound plus CA-125 measurement and prophylactic salpingo-oophorectomy in women at different risk levels of ovarian cancer: the modena study group cohort study.Oncology. 2017; 93https://doi.org/10.1159/000479155
- Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 or BRCA2 mutations.Br J Cancer. 2004; 91https://doi.org/10.1038/sj.bjc.6602239
- BRCA-associated cancers: role of imaging in screening, diagnosis, and management.Radiographics. 2017; 37https://doi.org/10.1148/rg.2017160144
- Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.J Natl Cancer Inst. 2009; 101https://doi.org/10.1093/jnci/djn442
- Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.Cochrane Database Syst Rev. 2016; 2016https://doi.org/10.1002/14651858.CD012464
- Risk reduction and survival benefit of prophylactic surgery in BRCA mutation carriers, a systematic review.Am J Surg. 2016; 212https://doi.org/10.1016/j.amjsurg.2016.06.010
- Genetic/familial high-risk assessment: breast, ovarian, and pancreatic, version 2.2021, NCCN clinical practice guidelines in Oncology.J Natl Compr Cancer Netw. 2021; : 19
- Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening.Ann Oncol. 2016; 27https://doi.org/10.1093/annonc/mdw327
- Cancer precursor lesions in the BRCA population at the time of prophylactic salpingo-oophorectomy: accuracy of assessment and potential surrogate marker for prevention.Gynecol Oncol. 2015; 138https://doi.org/10.1016/j.ygyno.2015.06.014
- Long-term outcomes following a diagnosis of ovarian cancer at the time of preventive oophorectomy among BRCA1 and BRCA2 mutation carriers.Int J Gynecol Cancer. 2020; 30https://doi.org/10.1136/ijgc-2019-001141
- Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutated patients: an evidence-based approach on what women should know.Cancer Treat Rev. 2017; 61https://doi.org/10.1016/j.ctrv.2017.09.005
- Outcome and prognostic impact of surgical staging in serous tubal intraepithelial carcinoma: a cohort study and systematic review.Clin Oncol. 2018; 30https://doi.org/10.1016/j.clon.2018.03.036
- ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease.Ann Oncol. 2019; 30https://doi.org/10.1093/annonc/mdz062
- Risk-reducing salpingo-oophorectomy in women at higher risk of ovarian and breast cancer: a single institution prospective series.Anticancer Res. 2017; 37https://doi.org/10.21873/anticanres.11948
- Efficacy of risk-reducing salpingo-oophorectomy in BRCA1–2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).Gynecol Oncol. 2021; 163https://doi.org/10.1016/j.ygyno.2021.08.021
- Occult tubal carcinoma after risk-reducing salpingo-oophorectomy: a systematic review.Obstet Gynecol. 2020; 135https://doi.org/10.1097/AOG.0000000000003702
- The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): a single-center prospective study.Eur J Obstet Gynecol Reprod Biol. 2020; 247https://doi.org/10.1016/j.ejogrb.2020.01.040
- Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.Ann Surg. 2004; 240https://doi.org/10.1097/01.sla.0000133083.54934.ae
- Occult and subsequent cancer incidence following risk-reducing surgery in BRCA mutation carriers.Gynecol Oncol. 2016; 143https://doi.org/10.1016/j.ygyno.2016.08.336
- Comparison of the classical method and SEE-FIM protocol in detecting microscopic lesions in fallopian tubes with gynecological lesions.J Pathology Translational Med. 2018; 52https://doi.org/10.4132/jptm.2016.06.17
- Uterine cancer after risk-reducing salpingo-oophorectomy without hysterectomy in women with BRCA Mutations.JAMA Oncol. 2016; 2https://doi.org/10.1001/jamaoncol.2016.1820
- BRCA1 and BRCA2 pathogenic variant carriers and endometrial cancer risk: a cohort study.Eur J Cancer. 2020; 136https://doi.org/10.1016/j.ejca.2020.05.030
- Endometrial cancer in germline BRCA mutation carriers: a systematic review and meta-analysis.J Minim Invasive Gynecol. 2021; 28https://doi.org/10.1016/j.jmig.2020.11.023
- Role of routine peritoneal biopsies during risk reducing salpingo-oophorectomy (RRSO).Geburtshilfe Frauenheilkd. 2021; 81https://doi.org/10.1055/a-1395-7715
- The role of routine peritoneal and omental biopsies at risk-reducing salpingo-oophorectomy.J Minim Invasive Gynecol. 2017; 24https://doi.org/10.1016/j.jmig.2017.03.001
- Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.J Clin Oncol. 2005; 23https://doi.org/10.1200/JCO.2005.04.109
Published online: July 18, 2022
Accepted: July 5, 2022
Received in revised form: June 23, 2022
Received: February 7, 2022
© 2022 Published by Elsevier Ltd.